CytomX Therapeutics, Inc. CTMX
Latest 10-Q
What changed in CytomX Therapeutics, Inc.'s latest quarterly report, compared with the one before.
Loading…
Insider trades
Open-market trades from Form 4. 10b5-1 marks a plan set in advance.Open-market buys and sales by officers, directors and 10% owners, from SEC Form 4. A plan set in advance is marked 10b5-1.
Loading…
13F holders
Funds that report this stock, checked against market prices.Fund managers with over $100 million in US-listed stocks file a 13F each quarter, up to 45 days after quarter end. Long positions only.
Loading…
Trades by members of Congress
Disclosed in dollar ranges, up to 45 days after the trade.Members of Congress, their spouses and dependent children report trades in dollar ranges, up to 45 days after the trade.
Loading…
Executive-branch trades
1 tradeTrades in CytomX Therapeutics, Inc. reported by the President, Cabinet members and other senior executive-branch officials. Amounts are ranges.Form 278-T is the periodic transaction report that senior executive-branch officials file with the Office of Government Ethics. They must report each trade over $1,000 within 30 days of being notified of it, and no later than 45 days after the trade. Amounts are ranges, not exact figures.
| Official | AssetThe form has no ticker column. The asset is shown as the filer wrote it. We add a ticker link only when we could match the asset to a listed company. | Type | Traded | AmountThe form asks for a range, such as $1,001 - $15,000, not an exact amount. A line can be left blank when the filer's note says the amount was not more than $1,000. | Filed | Report |
|---|---|---|---|---|---|---|
| Eric S Lander Director, Office of Science and Technology Policy | CYTOMX THERAPEUTICS INC | Sale | Jun 10, 2021 | $15,001 - $50,000 | Aug 25, 2021 | OGE Form 278-T ↗ |
Lobbying
What CytomX Therapeutics, Inc. and its lobbying firms report each quarter.A company that lobbies with its own staff reports its expenses; a lobbying firm it hires reports the income it received. We count both.
Loading…
H-1B labor applications at CytomX Therapeutics, Inc.
1 certified in 12 moLabor condition applications decided by the Department of Labor, matched to CytomX Therapeutics, Inc. by employer name. An application is not a hire.
Median yearly wage offered, full-time certified applications, Jul 2025 to Jun 2026: —The wage the employer offered, as filed, with its unit. The yearly figure restates it per year (hourly x 2,080, weekly x 52, every two weeks x 26, monthly x 12) from the low end of the offered range. It is not what the worker was paid.
| Quarter | Certified | All decided | Workers asked for |
|---|---|---|---|
| 2024 Q3 | 2 | 2 | 2 |
| 2024 Q4 | 0 | 0 | 0 |
| 2025 Q1 | 0 | 0 | 0 |
| 2025 Q2 | 0 | 0 | 0 |
| 2025 Q3 | 0 | 0 | 0 |
| 2025 Q4 | 0 | 0 | 0 |
| 2026 Q1 | 0 | 0 | 0 |
| 2026 Q2 | 1 | 2 | 1 |
| Job title | Applications | Median wage |
|---|---|---|
| Manager, Clinical Data Management | 1 | — |
We match the employer's name to a public company automatically, including a reviewed list of subsidiaries. A subsidiary can be missed and a similar name can be matched wrongly. The files carry no worker names.
Institutional ownership over time
How many funds reported holding the stock at the end of each quarter, and how many shares they held between them.
Loading…
More filings and data
Each opens the table.
About the company
The basics from the company’s SEC registration.
Loading…
Adjusted for stock splits; not for dividends. Where prices come from.
Live chart
Intraday and historical prices from TradingView. Quotes may be delayed.
Information, not investment advice. Company matching is automatic; check the source before relying on one row.